This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Reviewing the data presented at ACR 2024 from the Phase 3 PHOENYCS GO clinical trial of Dapirolizumab pegol (DZP) in patients with SLE

Ticker(s): UCBJY, BIIB

Who's the expert?

Institution: Premier Rheumatology & Rehabilitation 

  • Rheumatologist at private practice in NY .
  • Currently manages 10 patients with IgG-mediated autoimmune diseases.
  • Active in academics, publishing in various peer reviewed journals on interesting topics and cases in Rheumatology.

Interview Goal
to discuss the current treatment landscape and the potential of Dapirolizumab pegol (DZP) for the reduction of SLE disease activity.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.